News from ceregene, inc

May 21, 2013, 07:00 ET

Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study

Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical...

Apr 19, 2013, 14:00 ET

Ceregene Reports Data From Parkinson's Disease Phase 2b Study

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin),...

Mar 13, 2013, 07:00 ET

Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial

Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy...

May 17, 2012, 07:00 ET

Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data...

Dec 01, 2011, 07:00 ET

Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease

 Ceregene, Inc. reported today that it has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the...

Feb 15, 2011, 07:00 ET

Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in...

Feb 03, 2011, 09:00 ET

Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin)...

Nov 11, 2010, 07:00 ET

Ceregene Raises $11.5 Million in Series D Financing

Ceregene, Inc., a biopharmaceutical company, announced today that it has closed its Series D preferred financing in the amount of $11.5 million....

Oct 19, 2010, 12:26 ET

Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study...

Jun 22, 2010, 12:30 ET

The Michael J. Fox Foundation Awards $2.5 Million to Support Ceregene's New Phase 2 Neurturin Clinical Study for Parkinson's Disease

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120....

Apr 28, 2010, 07:00 ET

Ceregene has Initiated a New Phase 1/2 Trial Of CERE-120 for Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a...

Aug 05, 2009, 09:00 ET

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients...

May 27, 2009, 07:00 ET

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- Ceregene, Inc. today reported additional clinical...

Nov 26, 2008, 09:15 ET

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients...

Nov 04, 2008, 09:00 ET

Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health

Ceregene, Inc., a biopharmaceutical company, today announced that the University of California, San Diego (UCSD) has received a $5.4 million grant...

Apr 23, 2008, 01:00 ET

Ceregene Announces Two Key Additions to Leadership Team

SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its...

Jan 07, 2008, 00:00 ET

Ceregene to Present at JPMorgan 26th Annual Healthcare Conference

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that Jeffrey M. Ostrove, Ph.D., president and chief executive...

Dec 06, 2007, 00:00 ET

Ceregene Promotes Dr. Raymond Bartus to Executive Vice President

SAN DIEGO, Dec. 6 /PRNewswire/ -- Ceregene, Inc. today announced the promotion of Raymond T. Bartus, Ph.D., to the position of executive vice...

Oct 02, 2007, 01:00 ET

Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer

SAN DIEGO, Oct. 2 /PRNewswire/ -- Ceregene, Inc., announced today that it has appointed Joao Siffert, M.D. to the position of vice president and...

Sep 21, 2005, 01:00 ET

Ceregene Reports Initiation of Phase 1 Clinical Trial of Novel Gene Therapy for Patients With Parkinson's Disease

SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Ceregene announced today that patient treatment is underway in its Phase I study of CERE-120 to...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer